Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

DRUGBRIGHT MINDS BIOSCIENCES INC.

Nasdaq · CIK 0001827401
Filer category<br>Emerging growth company
Entity typeother
SIC2834 Pharmaceutical Preparations
FY end0930
XBRL facts77

Identity from submissions API

NameBRIGHT MINDS BIOSCIENCES INC.
CIK0001827401
TickersDRUG
ExchangesNasdaq
Entity typeother
Category<br>Emerging growth company
SIC2834 Pharmaceutical Preparations
EIN000000000
LEI—
Fiscal year end0930
State of incorporationA1 British Columbia, Canada
Phone6474072515
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
400 N ABERDEEN ST SUITE 900
CHICAGO
IL
60642
IL
Mailing address
400 N ABERDEEN ST SUITE 900
CHICAGO
IL
60642
IL

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

No Financialist filing articles yet for this CIK.

SEC filings

182 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001172661-26-005294 005-94288 261559145 34 10112
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001213900-26-120152 005-94288 261555522 34 13699
2026-11-02 6-K f6k-20261102drug.htm 0002060755-26-000063 001-40997 261512825 34 25368
2026-10-02 6-K FORM 6-K 0001062993-26-005170 001-40997 261437847 34 22191
2026-10-01 6-K FORM 6-K 0001062993-26-005123 001-40997 261428478 34 23739
2026-08-17 6-K FORM 6-K 0001062993-26-004442 001-40997 261284198 34 817494
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001172661-26-003688 005-94288 261279671 34 10076
2026-08-13 S-8 FORM S-8 0001062993-26-004235 333-298286 261269542 33 488373 1 1
2026-08-12 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000919574-26-004968 005-94288 261266229 34 12555
2026-07-02 SCHEDULE 13D/A xslSCHEDULE_13D_X02/primary_doc.xml 0001062993-26-003506 005-94288 261153125 34 14277
2026-06-03 6-K FORM 6-K 0001062993-26-003005 001-40997 261058781 34 4259018
2026-06-02 6-K FORM 6-K 0001062993-26-002975 001-40997 261054329 34 12473
2026-05-28 6-K f6k-20260526.htm 0002060755-26-000031 001-40997 261028156 34 12291
2026-05-20 6-K FORM 6-K 0001062993-26-002801 001-40997 261000763 34 822459
2026-05-15 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000902664-26-002546 005-94288 26989530 34 15161
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001274173-26-000135 005-94288 26984893 34 12348
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001274173-26-000134 005-94288 26984890 34 12348
2026-05-12 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001213900-26-055371 005-94288 26970629 34 13603
2026-04-30 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000929638-26-001709 005-94288 26925303 34 9801
2026-04-30 4 xslF345X06/form4.xml 0000929638-26-001708 8887
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001274173-26-000081 005-94288 26642339 34 12268
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001831942-26-000007 005-94288 26641846 34 11515
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001193125-26-054519 005-94288 26640549 34 10680
2026-02-13 6-K FORM 6-K 0001062993-26-000881 001-40997 26628689 34 827500
2026-02-06 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001172661-26-000518 005-94288 26607151 34 10708
2026-01-09 6-K FORM 6-K 0001062993-26-000151 001-40997 26523210 34 22672
2026-01-09 6-K FORM 6-K 0001062993-26-000138 001-40997 26521051 34 267696
2026-01-09 424B5 FORM 424B5 0001062993-26-000136 333-289851 26521021 33 401953
2026-01-08 6-K f6k20260107.htm 0002060755-26-000009 001-40997 26517201 34 26921
2026-01-07 6-K FORM 6-K 0001062993-26-000102 001-40997 26516664 34 5986
2026-01-07 FWP FORM FWP 0001062993-26-000098 333-289851 26515427 34 4877850
2026-01-07 FWP FORM FWP 0001062993-26-000090 333-289851 26513842 34 4876184
2026-01-07 424B5 FORM 424B5 0001062993-26-000089 333-289851 26513840 33 430298
2026-01-07 6-K f6k20260106launch.htm 0002060755-26-000007 001-40997 26513553 34 25788
2026-01-06 6-K f6k20260106nr.htm 0002060755-26-000005 001-40997 26512871 34 30373
2026-01-05 6-K f6k-20260105.htm 0002060755-26-000002 001-40997 26507915 34 12601
2025-12-23 F-X FORM F-X 0001437749-25-038731 001-40997 251601841 33 36059
2025-12-23 40-F FORM 40-F 0001437749-25-038729 001-40997 251601838 34 9093645 1 1
2025-11-17 6-K FORM 6-K 0001062993-25-016913 001-40997 251491900 34 33953
2025-11-17 6-K/A FORM 6-K/A 0001062993-25-016909 001-40997 251490955 34 43915
2025-11-14 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001213900-25-111137 005-94288 251488745 34 21070
2025-11-13 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-004874 005-94288 251475699 34 15494
2025-11-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001214659-25-016262 005-94288 251469027 34 9469
2025-11-07 6-K FORM 6-K 0001062993-25-016559 001-40997 251463113 34 12801
2025-11-07 6-K FORM 6-K 0001062993-25-016557 001-40997 251462870 34 34677
2025-09-05 6-K f6k-20250904.htm 0002060755-25-000036 001-40997 251294682 34 17408
2025-09-02 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-002807 333-289851 251287651 33 1712
2025-08-28 CORRESP filename1.htm 0001062993-25-015036 26625
2025-08-27 UPLOAD filename1.pdf 0000000000-25-009199 333-289851 40023
2025-08-26 F-3 FORM F-3 0001062993-25-014903 333-289851 251252268 33 821338 1 1
2025-08-15 6-K FORM 6-K 0001062993-25-014464 001-40997 251221754 34 787219
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001274173-25-000208 005-94288 251215567 34 10587
2025-08-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001214659-25-011955 005-94288 251210506 34 9398
2025-08-11 6-K FORM 6-K 0001062993-25-014005 001-40997 251199919 34 765883
2025-05-28 6-K f6k-20250528.htm 0001183740-25-000037 001-40997 25995183 34 11204
2025-05-21 6-K f6k-20250520.htm 0002060755-25-000016 001-40997 25970567 34 23092
2025-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-013183 005-94288 25954889 34 18768
2025-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000950170-25-072739 005-94288 25954094 34 10310
2025-05-14 6-K f6k-20250513.htm 0002060755-25-000012 001-40997 25942078 34 23039
2025-04-29 6-K f6k-20250428.htm 0001183740-25-000033 001-40997 25882149 34 19675
2025-04-08 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001214659-25-005583 005-94288 25821592 34 9283
2025-04-07 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001274173-25-000106 005-94288 25818204 34 10586
2025-03-05 6-K f6k-20250304.htm 0001183740-25-000029 001-40997 25707626 34 29135
2025-02-24 6-K f6k-20250224.htm 0001183740-25-000026 001-40997 25655391 34 10881
2025-02-14 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-000478 333-284694 25632359 33 1718
2025-02-14 424B3 FORM 424B3 0001062993-25-002569 333-284694 25630209 33 206119
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-001021 005-94288 25628435 34 11854
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001493152-25-006845 005-94288 25628324 34 9235
2025-02-14 6-K FORM 6-K 0001062993-25-002353 001-40997 25622295 34 719043
2025-02-12 CORRESP filename1.htm 0001062993-25-002152 25495
2025-02-11 UPLOAD filename1.pdf 0000000000-25-001502 333-284694 39987
2025-02-10 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001214659-25-002303 005-94288 25604789 34 9283
2025-02-07 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001274173-25-000016 005-94288 25599950 34 10444
2025-02-05 F-3 FORM F-3 0001062993-25-001662 333-284694 25590699 33 580258
2025-01-08 6-K f6k-20250107im.htm 0001183740-25-000008 001-40997 25516120 34 18975
2024-12-31 20-F FORM 20-F 0001062993-24-021301 001-40997 241590899 34 8328391 1 1
2024-11-21 6-K FORM 6-K 0001062993-24-019452 001-40997 241482949 34 19193
2024-11-19 D xslFormDX01/primary_doc.xml 06b 0001183740-24-000091 021-529842 241474914 33 9922
2024-11-12 SC 13G SC 13G 0001104659-24-116794 005-94288 241448376 34 77044
2024-11-06 4 xslF345X05/form4.xml 0000929638-24-003752 6891
2024-11-06 SC 13G/A AMENDMENT NO. 1 0000929638-24-003750 005-94288 241430893 34 63926
2024-11-05 SC 13D/A FORM SC 13D/A 0001062993-24-018312 005-94288 241427196 34 32979
2024-11-05 SC 13D/A FORM SC 13D/A 0001062993-24-018310 005-94288 241427182 34 33491
2024-11-05 6-K FORM 6-K 0001062993-24-018274 001-40997 241425026 34 17371
2024-10-25 SC 13G formsc13g.htm 0001493152-24-042515 005-94288 241397084 34 94390
2024-10-23 SC 13G drug13g.htm 0000935836-24-000636 005-94288 241390216 34 61756
2024-10-23 SC 13G BRIGHT MINDS BIOSCIENCES INC. 0000902664-24-005963 005-94288 241390205 34 70444
2024-10-22 SC 13G sc13g.htm 0000929638-24-003553 005-94288 241386350 34 111450
2024-10-22 SC 13G/A SC 13G/A 0001104659-24-110554 005-94288 241386342 34 124925
2024-10-22 D xslFormDX01/primary_doc.xml 06b 0001183740-24-000085 021-527406 241384486 33 10077
2024-10-21 6-K f6k20241021.htm 0001183740-24-000084 001-40997 241383412 34 19595
2024-10-18 6-K f6k20241018.htm 0001183740-24-000081 001-40997 241380742 34 20459
2024-10-17 4 xslF345X05/form4.xml 0000929638-24-003542 29577
2024-10-17 3 xslF345X02/form3.xml 0000929638-24-003540 7829
2024-10-16 SC 13G SC 13G 0001193125-24-238029 005-94288 241374099 34 65494
2024-10-16 6-K f6k-20241015.htm 0001183740-24-000079 001-40997 241373829 34 14109
2024-10-16 6-K FORM 6-K 0001171843-24-005653 001-40997 241373815 34 12486
2024-10-03 6-K FORM 6-K 0001171843-24-005482 001-40997 241350410 34 14657
2024-09-12 6-K f6k20240912.htm 0001183740-24-000073 001-40997 241294436 34 23312
2024-08-15 6-K FORM 6-K 0001062993-24-015119 001-40997 241210400 34 711473
2024-05-17 6-K FORM 6-K 0001062993-24-010545 001-40997 24957360 34 709902
2024-05-17 6-K FORM 6-K 0001062993-24-010535 001-40997 24957324 34 911318
2024-05-03 D xslFormDX01/primary_doc.xml 06b 0001183740-24-000039 021-512284 24910351 33 11324
2024-02-26 SC 13D/A sc13da2-im.htm 0001183740-24-000021 005-94288 24681444 34 35071
2024-02-26 SC 13D/A sc13da1-im.htm 0001183740-24-000019 005-94288 24681408 34 34938
2024-02-13 6-K FORM 6-K 0001062993-24-002875 001-40997 24622394 34 702430
2024-01-18 SC 13D sch13d-im.htm 0001183740-24-000006 005-94288 24540967 34 34043
2023-12-29 20-F FORM 20-F 0001062993-23-023281 001-40997 231528097 34 9140120 1 1
2023-12-26 6-K f6k20231222.htm 0001183740-23-000134 001-40997 231511065 34 18752
2023-12-08 6-K FORM 6-K 0001062993-23-022132 001-40997 231473846 34 17166
2023-08-15 6-K FORM 6-K 0001062993-23-016456 001-40997 231172718 34 755857
2023-08-08 6-K f6k20230808drug.htm 0001183740-23-000098 001-40997 231151778 34 33063
2023-07-20 6-K f6k20230719drug.htm 0001183740-23-000090 001-40997 231099234 34 27424
2023-07-12 6-K f6k.htm 0001183740-23-000087 001-40997 231085173 34 18335
2023-06-22 6-K f6k-20230622drug.htm 0001183740-23-000077 001-40997 231033181 34 17826
2023-05-15 6-K FORM 6-K 0001062993-23-011135 001-40997 23924302 34 744304
2023-04-19 6-K f6k-20230419drug.htm 0001183740-23-000053 001-40997 23829950 34 20276
2023-04-10 6-K FORM 6-K 0001171843-23-002211 001-40997 23809736 34 14387
2023-03-02 6-K f6k-20230301drug.htm 0001183740-23-000039 001-40997 23698144 34 938063
2023-02-27 6-K f6k-20230227drug.htm 0001183740-23-000032 001-40997 23676686 34 33837
2023-02-17 6-K f6k-20230217drug.htm 0001183740-23-000027 001-40997 23641875 34 21301
2023-02-08 6-K f6k-20230208drug.htm 0001183740-23-000024 001-40997 23600165 34 17441
2023-02-07 6-K FORM 6-K 0001062993-23-002395 001-40997 23596079 34 689962
2023-01-30 6-K f6k-20230109drug.htm 0001183740-23-000012 001-40997 23568346 34 13382
2023-01-27 6-K f6k-20230127drug.htm 0001183740-23-000009 001-40997 23564311 34 17483
2022-12-29 20-F FORM 20-F 0001062993-22-024547 001-40997 221499259 34 9359091 1 1
2022-12-06 6-K FORM 6-K 0001062993-22-023349 001-40997 221446078 34 17541
2022-11-29 6-K FORM 6-K 0001062993-22-022863 001-40997 221427707 34 18571
2022-11-23 6-K f6k-20221123drug.htm 0001183740-22-000182 001-40997 221417140 34 19159
2022-09-14 D xslFormDX01/primary_doc.xml 06b 0001183740-22-000165 021-458931 221243794 33 10869
2022-09-08 6-K f6k-20220907drug.htm 0001183740-22-000164 001-40997 221233771 34 19642
2022-09-08 6-K f6k-20220831drug.htm 0001183740-22-000162 001-40997 221233768 34 20998
2022-09-01 D xslFormDX01/primary_doc.xml 06b 0001183740-22-000159 021-457729 221220649 33 11294
2022-08-30 6-K f6k-20220830drug.htm 0001183740-22-000158 001-40997 221215573 34 14598
2022-08-29 6-K f6k-20220826drug.htm 0001183740-22-000155 001-40997 221207001 34 1143617
2022-08-24 6-K f6k-20220823drug.htm 0001183740-22-000153 001-40997 221190770 34 18170
2022-08-23 6-K f6k-20220822drug.htm 0001183740-22-000149 001-40997 221188120 34 15932
2022-08-18 6-K f6k-20220818drug.htm 0001183740-22-000146 001-40997 221177554 34 10884
2022-08-15 6-K FORM 6-K 0001062993-22-017893 001-40997 221161959 34 647606
2022-05-16 6-K FORM 6-K 0001062993-22-012649 001-40997 22930947 34 645265
2022-05-12 6-K f6k-20220512drug.htm 0001183740-22-000111 001-40997 22917582 34 25865
2022-05-03 D xslFormDX01/primary_doc.xml 06b 0001183740-22-000098 021-444201 22885689 33 11804
2022-05-03 D xslFormDX01/primary_doc.xml 06b 0001183740-22-000097 021-444200 22885673 33 11803
2022-05-02 6-K f6k-20220502drug.htm 0001183740-22-000092 001-40997 22881373 34 26950
2022-04-19 6-K f6k-20220419drug.htm 0001183740-22-000086 001-40997 22834873 34 19391
2022-03-14 6-K f6k-20220314drug.htm 0001183740-22-000063 001-40997 22736622 34 18445
2022-03-08 6-K f6k-20220308drug.htm 0001183740-22-000059 001-40997 22721398 34 19113
2022-03-02 6-K f6k-20220301drug.htm 0001183740-22-000047 001-40997 22700470 34 676076
2022-02-15 6-K FORM 6-K 0001062993-22-004353 001-40997 22636548 34 617600
2022-01-18 20-F/A FORM 20-F/A 0001062993-22-001182 001-40997 22535694 34 6350702 1 1
2022-01-05 6-K f6k-20220104drug.htm 0001183740-22-000002 001-40997 22508385 34 18351
2021-12-29 20-F FORM 20-F 0001062993-21-013611 001-40997 211528759 34 2405775 1 1
2021-11-30 6-K f6k-20211130drug.htm 0001183740-21-000299 001-40997 211458941 34 21307
2021-11-04 CERT 8A CERT 0001354457-21-001291 001-40997 211379697 34 185055
2021-11-03 6-K f6k-20211103drug.htm 0001183740-21-000281 001-40997 211374417 34 28336
2021-11-02 8-A12B FORM 8-A12B 0001062993-21-010071 001-40997 211368482 34 12996
2021-10-19 6-K FORM 6-K 0001062993-21-009705 000-56296 211330346 34 12691
2021-09-27 6-K FORM 6-K 0001062993-21-008947 000-56296 211282725 34 25553
2021-09-27 UPLOAD filename1.pdf 0000000000-21-011744 39862
2021-09-17 6-K FORM 6-K 0001062993-21-008705 000-56296 211259160 34 560769
2021-09-17 6-K FORM 6-K 0001062993-21-008689 000-56296 211259080 34 15936
2021-09-17 20FR12G/A FORM 20FR12G/A 0001062993-21-008685 000-56296 211259073 34 1413213
2021-09-16 CORRESP filename1.htm 0001062993-21-008687 15379
2021-09-15 UPLOAD filename1.pdf 0000000000-21-011200 44626
2021-08-27 CORRESP filename1.htm 0001062993-21-007990 18434
2021-08-27 20FR12G/A FORM 20FR12G/A 0001062993-21-007988 000-56296 211214254 34 1411484
2021-08-24 UPLOAD filename1.pdf 0000000000-21-010384 44839
2021-08-18 6-K FORM 6-K 0001062993-21-007717 000-56296 211187538 34 19756
2021-08-13 CORRESP filename1.htm 0001062993-21-007435 23938
2021-08-13 20FR12G/A FORM 20FR12G/A 0001062993-21-007433 000-56296 211169814 34 1415874
2021-08-04 UPLOAD filename1.pdf 0000000000-21-009590 46023
2021-07-29 20FR12G/A FORM 20FR12G/A 0001062993-21-006791 000-56296 211124443 34 1636959
2021-07-28 CORRESP filename1.htm 0001062993-21-006793 50141
2021-07-16 UPLOAD filename1.pdf 0000000000-21-008829 59354
2021-06-25 D xslFormDX01/primary_doc.xml 06b 0001183740-21-000131 021-404247 211044347 33 11780
2021-06-17 20FR12G FORM 20FR12G 0001062993-21-005781 000-56296 211025689 34 4113512
2021-05-04 D xslFormDX01/primary_doc.xml 06b 0001183740-21-000097 021-398178 21887827 33 10806
2021-03-23 D xslFormDX01/primary_doc.xml 06b 0001183740-21-000060 021-393110 21762601 33 11346
2020-11-17 D xslFormDX01/primary_doc.xml 06b 0001183740-20-000249 021-380780 201320355 33 11232
2020-11-17 D xslFormDX01/primary_doc.xml 06b 0001183740-20-000248 021-380778 201320308 33 10820
2020-10-07 D xslFormDX01/primary_doc.xml 06b 0001183740-20-000216 021-377277 201227659 33 7253
2020-10-06 D xslFormDX01/primary_doc.xml 06b 0001183740-20-000215 021-377274 201227562 33 7326

Latest XBRL company facts

One latest value per concept from companyfacts (77 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 4.52M 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ffd NetFeeAmt NetFeeAmt USD 24,472.45 2026-08-12 S-8 2026-08-13 0001062993-26-004235
ffd TtlFeeAmt TtlFeeAmt USD 24,472.45 2026-08-12 S-8 2026-08-13 0001062993-26-004235
ffd TtlOfferingAmt TtlOfferingAmt USD 177.21M 2026-08-12 S-8 2026-08-13 0001062993-26-004235
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-08-12 S-8 2026-08-13 0001062993-26-004235
ifrs-full AccountingProfit AccountingProfit CAD -2.80M 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full AccrualsClassifiedAsCurrent AccrualsClassifiedAsCurrent CAD 41,751 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full AdditionsToRightofuseAssets AdditionsToRightofuseAssets CAD 124,506 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full AdjustedWeightedAverageShares AdjustedWeightedAverageShares shares 4.31M 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full AdjustmentsForDecreaseIncreaseInPrepaidExpenses AdjustmentsForDecreaseIncreaseInPrepaidExpenses CAD -188,936 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables CAD 0 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full AdjustmentsForDepreciationAndAmortisationExpense AdjustmentsForDepreciationAndAmortisationExpense CAD 73,357 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill CAD 0 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full AdjustmentsForIncreaseDecreaseInTradeAccountPayable AdjustmentsForIncreaseDecreaseInTradeAccountPayable CAD 241,992 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full AdjustmentsForSharebasedPayments AdjustmentsForSharebasedPayments CAD 839,771 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full AdjustmentsForUnrealisedForeignExchangeLossesGains AdjustmentsForUnrealisedForeignExchangeLossesGains CAD -10,126 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full ApplicableTaxRate ApplicableTaxRate pure 0.26 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full Assets Assets CAD 6.10M 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full BasicAndDilutedEarningsLossPerShare BasicAndDilutedEarningsLossPerShare CAD/shares -0.96 2020-10-01 2021-09-30 2021 FY 20-F/A 2022-01-18 0001062993-22-001182
ifrs-full BasicEarningsLossPerShare BasicEarningsLossPerShare CAD/shares -0.65 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full CashAndCashEquivalents CashAndCashEquivalents CAD 5.72M 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full CashFlowsFromUsedInFinancingActivities CashFlowsFromUsedInFinancingActivities CAD 810,572 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full CashFlowsFromUsedInOperatingActivities CashFlowsFromUsedInOperatingActivities CAD -1.85M 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full CashOutflowForLeases CashOutflowForLeases CAD 89,730 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full CurrentAssets CurrentAssets CAD 5.99M 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full CurrentLeaseLiabilities CurrentLeaseLiabilities CAD 79,384 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full CurrentLiabilities CurrentLiabilities CAD 528,683 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full CurrentPrepaidExpenses CurrentPrepaidExpenses CAD 216,628 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full CurrentTaxAssetsCurrent CurrentTaxAssetsCurrent CAD 50,224 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised CAD 0 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full DepreciationRightofuseAssets DepreciationRightofuseAssets CAD 73,357 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full DilutedEarningsLossPerShare DilutedEarningsLossPerShare CAD/shares -0.65 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full DirectorsRemunerationExpense DirectorsRemunerationExpense CAD 493,793 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full EffectOfExchangeRateChangesOnCashAndCashEquivalents EffectOfExchangeRateChangesOnCashAndCashEquivalents CAD 11,720 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full Equity Equity CAD 5.54M 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full EquityAndLiabilities EquityAndLiabilities CAD 6.10M 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full ExpenseByNature ExpenseByNature CAD 2.83M 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets CAD 839,771 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full ExpenseFromSharebasedPaymentTransactionsWithEmployees ExpenseFromSharebasedPaymentTransactionsWithEmployees CAD 880,615 2020-10-01 2021-09-30 2021 FY 20-F/A 2022-01-18 0001062993-22-001182
ifrs-full GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss CAD -9,312 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full GeneralAndAdministrativeExpense GeneralAndAdministrativeExpense CAD 264,009 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill CAD 0 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full IncomeTaxExpenseContinuingOperations IncomeTaxExpenseContinuingOperations CAD 0 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full IncreaseDecreaseInCashAndCashEquivalents IncreaseDecreaseInCashAndCashEquivalents CAD -1.04M 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full IncreaseDecreaseInNumberOfSharesOutstanding IncreaseDecreaseInNumberOfSharesOutstanding shares 4.05M 2019-07-01 2019-07-31 2021 FY 20-F/A 2022-01-18 0001062993-22-001182
ifrs-full IncreaseDecreaseThroughExerciseOfWarrantsEquity IncreaseDecreaseThroughExerciseOfWarrantsEquity CAD 253,440 2022-10-01 2023-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets CAD 96 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full IncreaseDecreaseThroughSharebasedPaymentTransactions IncreaseDecreaseThroughSharebasedPaymentTransactions CAD 839,771 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full IntangibleAssetsAndGoodwill IntangibleAssetsAndGoodwill CAD 0 2022-09-30 2022 FY 20-F 2022-12-29 0001062993-22-024547
ifrs-full InterestExpenseOnLeaseLiabilities InterestExpenseOnLeaseLiabilities CAD 8,945 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full IssuedCapital IssuedCapital CAD 35.42M 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full KeyManagementPersonnelCompensation KeyManagementPersonnelCompensation CAD 1.27M 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full KeyManagementPersonnelCompensationSharebasedPayment KeyManagementPersonnelCompensationSharebasedPayment CAD 493,793 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full LeaseLiabilities LeaseLiabilities CAD 118,960 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full Liabilities Liabilities CAD 568,259 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full NoncurrentLeaseLiabilities NoncurrentLeaseLiabilities CAD 39,576 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full OtherCurrentReceivables OtherCurrentReceivables CAD 0 2023-09-30 2023 FY 20-F 2023-12-29 0001062993-23-023281
ifrs-full OtherReserves OtherReserves CAD 4.01M 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full PaymentsForShareIssueCosts PaymentsForShareIssueCosts CAD 0 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities CAD 89,730 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full ProceedsFromIssueOfOrdinaryShares ProceedsFromIssueOfOrdinaryShares CAD 80,980 2019-10-07 2020-09-28 2021 FY 20-F/A 2022-01-18 0001062993-22-001182
ifrs-full ProceedsFromIssuingOtherEquityInstruments ProceedsFromIssuingOtherEquityInstruments CAD 900,000 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full ProceedsFromIssuingShares ProceedsFromIssuingShares CAD 27.74M 2020-10-01 2021-09-30 2021 FY 20-F/A 2022-01-18 0001062993-22-001182
ifrs-full ProfessionalFeesExpense ProfessionalFeesExpense CAD 547,765 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full ProfitLoss ProfitLoss CAD -2.80M 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full ResearchAndDevelopmentExpense ResearchAndDevelopmentExpense CAD 1.18M 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full RetainedEarnings RetainedEarnings CAD -34.35M 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full RevenueFromInterest RevenueFromInterest CAD 30,133 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full RightofuseAssets RightofuseAssets CAD 117,658 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full SalesAndMarketingExpense SalesAndMarketingExpense CAD 41,600 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full ShareIssueRelatedCost ShareIssueRelatedCost CAD 26,976 2022-10-01 2023-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full TaxExpenseIncomeAtApplicableTaxRate TaxExpenseIncomeAtApplicableTaxRate CAD -727,974 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full TradeAndOtherCurrentPayables TradeAndOtherCurrentPayables CAD 449,299 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full TradeAndOtherCurrentPayablesToRelatedParties TradeAndOtherCurrentPayablesToRelatedParties CAD 61,061 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full TradeAndOtherCurrentPayablesToTradeSuppliers TradeAndOtherCurrentPayablesToTradeSuppliers CAD 407,548 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full WarrantReserve WarrantReserve CAD 455,573 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301
ifrs-full WeightedAverageShares WeightedAverageShares shares 4.31M 2023-10-01 2024-09-30 2024 FY 20-F 2024-12-31 0001062993-24-021301

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →